Kostas Athanasakis,1 Aikaterini Bilitou,2 Dawn Lee,3 Eleftheria Karampli,1 Apostolos Karavidas,4 John Parissis,5 Georgia Sykara,2 John Kyriopoulos1 1Department of Health Economics, National School of Public Health, Athens, Greece; 2Pfizer Hellas, Athens,
Athanasakis K +7 more
doaj
Bart, Bradley A., Nelson, Sarah
openaire +1 more source
Cardiorenal Effects of Switching from Eplerenone to Esaxerenone in Patients with Chronic Heart Failure and Hypertension: A Prospective Clinical Study. [PDF]
Sezai A +5 more
europepmc +1 more source
Initiation of eplerenone vs. spironolactone and all-cause mortality in HFrEF: linked database study. [PDF]
Svanström H, Hviid A, Pasternak B.
europepmc +1 more source
Functional and Structural Outcomes of Photodynamic Therapy (PDT) With or Without Eplerenone for Central Serous Chorioretinopathy. [PDF]
Gregori G +11 more
europepmc +1 more source
Pharmacovigilance profiles of three generations of mineralocorticoid receptor antagonists and network toxicology analysis. [PDF]
Lin HH +7 more
europepmc +1 more source
The impact of mineralocorticoid receptor antagonists on fat mass and fat metabolism. [PDF]
Afsar B, Afsar RE, Maddukuri G.
europepmc +1 more source
Late-gestation mineralocorticoid receptor antagonism lowers maternal blood pressure and attenuates placental insufficiency induced by leptin in pregnant mice. [PDF]
Sones JL.
europepmc +1 more source
Ultrawide-field indocyanine angiography changes post 12 weeks of eplerenone in central serous chorioretinopathy. [PDF]
Sagar A +9 more
europepmc +1 more source

